Glenmark Gets USFDA Nod For Anti-Cholesterol Drug


Drug firm Glenmark Pharmaceuticals today said it has received final approval from the USFDA for its generic version of Fenofibrate capsules used for lowering cholesterol.

The company has been granted final approval by the United States Food and Drug Administration (USFDA) for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg, Glenmark Pharmaceuticals said in a statement.

The company’s product is the generic version of Tricor Micronized capsules, 67 mg, 134 mg, and 200 mg of AbbVie Inc, it added.

Citing IMS Health February 2017, Glenmark said the Tricor Micronized capsules had annual sales of approximately $97.5 million.

The stock was trading at Rs. 869.20, up 0.74 per cent, on BSE.

Here's To Your Health
We're reporting in on the latest in health news, medical research, insurance coverage, plus managing your health and the health of the people you love.
We respect your privacy